Cardiotoxicity of Histone Deacetylase Inhibitor Depsipeptide in Patients with Metastatic Neuroendocrine Tumors
Open Access
- 1 July 2006
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 12 (13), 3997-4003
- https://doi.org/10.1158/1078-0432.ccr-05-2689
Abstract
Purpose: This phase II study was undertaken to assess objective response and toxicity of histone deacetylase inhibitor depsipeptide in patients with neuroendocrine tumors.Keywords
This publication has 14 references indexed in Scilit:
- A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemiaBlood, 2004
- Gene Silencing in Cancer in Association with Promoter HypermethylationNew England Journal of Medicine, 2003
- A phase I trial of Depsipeptide (FR901228) in patients with advanced cancerJournal of Experimental Therapeutics and Oncology, 2002
- Histone-deacetylase inhibitors: novel drugs for the treatment of cancerNature Reviews Drug Discovery, 2002
- Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case reportBlood, 2001
- Hepatic Arterial Chemoembolization in the Management of Advanced Digestive Endocrine TumorsDigestion, 2000
- Measurements of chromogranin A, chromogranin B (secretogranin I), chromogranin C (secretogranin II) and pancreastatin in plasma and urine from patients with carcinoid tumours and endocrine pancreatic tumoursJournal of Endocrinology, 1995
- Endocrine tumors of the gastrointestinal tract: systemic treatmentAnti-Cancer Drugs, 1994
- FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. III. Antitumor activities on experimental tumors in mice.The Journal of Antibiotics, 1994
- Optimal two-stage designs for phase II clinical trialsControlled Clinical Trials, 1989